Business
Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease
Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced the publication of its latest peer-reviewed observational study in a Springer Nature journal, Documenta Ophthalmologica, advancing the field's understanding of how to measure meaningful vision improvements in patients with severe vision loss in the real world.
About this update from Springer Nature Ag & Co. Kgaa
[{"type":"text","content":"DALLAS, March 23, 2026 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced the publication of its latest peer-reviewed observational study in a Springer Nature journal, Documenta Ophthalmologica, advancing the field's understanding of how to measure meaningful vision improvements in patients with severe vision loss in the real world.","length":544,"tagName":"p"},{"type":"image","alt":"Nanoscope Therapeutics Logo (PRNewsfoto/Nanoscope Therapeutics)","displaySize":"","headline":null,"caption":"Nanoscope Therapeutics Logo (PRNewsfoto/Nanoscope Therapeutics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":81,"url":"https://media.zenfs.com/en/prnewswire.com/c7763a47ce9d084fd0a8fbf1bc78300d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3ilzwbQR6G9UQvMcoAJXgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE0Mw--/https://media.zenfs.com/en/prnewswire.com/c7763a47ce9d084fd0a8fbf1bc78300d","width":400,"height":81}},"href":"https://mma.prnewswire.com/media/2718911/NSCOPE_nu_Horizontal_2Color_1200px_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The study underscores a critical need for testing in patients suffering from loss of vision due to loss of rod and cone functions, highlighting tools that accurately capture functional improvements and patient experience, and can be used in standard retina workflows.","length":267,"tagName":"p"},{"type":"text","content":""While best-corrected visual acuity (BCVA) has long been the gold standard in ophthalmology, it can be supplemented with new ways to assess how patients with severe vision loss navigate their daily lives," said Samarendra Mohanty, Ph.D., the senior author and Chief Scientific Officer at Nanoscope Therapeutics, "I'm proud that our peer-reviewed findings can help clinicians and treating physicians feel confident in using these tests to assess their patients' functional vision."","length":508,"tagName":"p"},{"type":"text","content":"The publication highlights findings from a prospective, observational study in 35 subjects, 25 with severe vision loss due to retinitis pigmentosa (RP) and 10 wit...